Page last updated: 2024-08-22

cladribine and Local Neoplasm Recurrence

cladribine has been researched along with Local Neoplasm Recurrence in 42 studies

Research

Studies (42)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (11.90)	18.2507
2000's	12 (28.57)	29.6817
2010's	13 (30.95)	24.3611
2020's	12 (28.57)	2.80

Authors

Authors	Studies
Alexandri, N; Brochet, B; Havrdova, EK; Hupperts, R; Keller, B; Langdon, D; Lechner-Scott, J; Montalban, X; Nolting, A; Patti, F; Piehl, F; Rejdak, K; Selmaj, K; Solari, A; Valis, M	1
Gao, Q; Lu, M; Xiao, L; Xu, B	1
Aladjem, MI; Epner, EM; Evans, J; Fox, T; Fu, H; Hasanali, ZS; Kester, M; LeBlanc, FR; Leshchenko, VV; Liao, J; Loughran, TP; Martin, MM; Parekh, S; Pu, JJ; Sharma, K; Shimko, S; Spurgeon, SE; Stuart, A; Zhang, Y	1
Appelbaum, J; Curley, N; Estey, EH; Gooley, T; Halpern, AB; Hendrie, PC; Kopmar, NE; Lim, J; Percival, MM; Russell, K; Schonhoff, K; Scott, BL; Shaw, C; Walter, RB	1
Aydemir, A; Borsi, L; Boyko, A; Correale, J; Edan, G; Freedman, MS; Giovannoni, G; Leist, T; Montalban, X; Rammohan, K; Stefoski, D; Verdun di Cantogno, E; Yamout, B	1
Baidildina, D; Bronin, G; Burtsev, E; Cherniak, E; Dzhukaeva, I; Erega, E; Evseev, D; Fink, O; Ignatova, A; Kalinina, I; Kotskaya, N; Litvin, E; Lyudovskikh, E; Maschan, A; Maschan, M; Novichkova, G; Osipova, D; Popov, A; Pristanskova, E; Purbueva, B; Raykina, E; Semchenkova, A; Vlasova, I; Voronin, K; Zhogov, V	1
Abičić, A; Adamec, I; Barun, B; Bašić Kes, V; Brecl Jakob, G; Cindrić, I; Drulović, J; Gabelić, T; Gomezelj, S; Gržinčić, T; Habek, M; Klivényi, P; Krbot Skorić, M; Lazibat, I; Mesaroš, Š; Pekmezović, T; Radulović, L; Rajda, C; Rimac, J	1
Chen, K; Jiang, H; Li, H; Shao, JB; Yang, JW; Zhang, N; Zhu, JS	1
Chen, XJ; Chen, YM; Guo, Y; Liu, F; Liu, LP; Liu, TF; Liu, XM; Quan Qi, B; Ruan, M; Yang, WY; Zhang, AL; Zhang, L; Zhu, XF; Zou, Y	1
Atkins, HL; Bose, G; Freedman, MS; Rush, C	1
Eisenberger, U; Fleischer, M; Gäckler, A; Hackert, J; Hagenacker, T; Kleinschnitz, C; Krämer, J; Kribben, A; Meuth, SG; Pfeuffer, S; Pfister, F; Pul, R; Ruck, T; Schönfelder, K; Schuh, H; Skuljec, J	1
Chen, X; Dong, T; Ji, J; Kuang, P; Li, J; Liu, J; Liu, T; Liu, Z; Shen, K; Zhang, C; Zhang, L	1
Cubitt, C; Komrokji, RS; Lancet, JE; List, AF; Mirza, AS; Nardelli, L; Padron, E; Pinilla-Ibarz, J; Sweet, K	1
Andrasiak, I; Rybka, J; Wrobel, T	1
Hu, Y; Huang, H; Jin, A; Jin, M; Luo, Y; Tan, Y; Wei, G; Wu, W; Yang, L; Yu, J	1
Cecconi, N; Cervetti, G; Galimberti, S; Ghio, F; Pelosini, M; Petrini, M	1
Audemard, A; Comoz, F; Crochette, R; Ficheux, M; Salaün, V	1
Drake, MT; Fishkin, PA; Inwards, DJ; Kurtin, PJ; Lair, BS; LaPlant, BR; Nikcevich, DA; Wender, DB; Witzig, TE	1
Abdel-Wahab, O; Andritsos, LA; Banerji, V; Barrientos, J; Blachly, JS; Call, TG; Catovsky, D; Dearden, C; Demeter, J; Else, M; Falini, B; Forconi, F; Gozzetti, A; Grever, MR; Ho, AD; Johnston, JB; Jones, J; Juliusson, G; Kraut, E; Kreitman, RJ; Larratt, L; Lauria, F; Lozanski, G; Montserrat, E; Parikh, SA; Park, JH; Polliack, A; Quest, GR; Rai, KR; Ravandi, F; Robak, T; Saven, A; Seymour, JF; Tadmor, T; Tallman, MS; Tam, C; Tiacci, E; Troussard, X; Zent, CS; Zenz, T; Zinzani, PL	1
Alexandrescu, DT; Dasanu, CA	1
Hoffman, MA	1
Bassi, S; Bertazzoni, P; Calabrese, L; Calleri, A; Gigli, F; Gregato, G; Laszlo, D; Liptrott, SJ; Martinelli, G; Nassi, L; Negri, M; Orlando, L; Preda, L; Pruneri, G; Rabascio, C; Radice, D; Sammassimo, S	1
Teh, TC; Wei, A	1
Fernandez, HF; George, TJ; Ho, VQ; Kharfan-Dabaja, MA; Komrokji, RS; Lancet, JE; List, AF; Pinilla-Ibarz, J; Price, SL; Wetzstein, GA	1
Bowman, WP; Campana, D; Cao, X; Dahl, G; Inaba, H; Jenkins, L; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Taub, JW	1
Aivado, M; Burger, J; Finke, J; Haas, R; Henze, L; Schulte, K	1
Burian, C; Goodman, GR; Koziol, JA; Saven, A	1
Bartl, R; Dietzfelbinger, H; Haferlach, T; Heinemann, V; Jehn, U	1
Choi, I; Nakashima, Y; Shimada, T; Uike, N; Yamada, Y; Yufu, Y	1
Chott, A; Du, MQ; Isaacson, PG; Raderer, M; Streubel, B; Ye, H	1
Chánová, M; Drahokoupilová, E; Mottl, H; Nekolná, M; Smelhaus, V; Starý, J	1
Arora, M; Barker, JN; Blazar, BR; Burns, LJ; DeFor, T; Douek, D; MacMillan, ML; Markova, M; Miller, JS; Repka, T; Tan, Y; Wagner, JE; Weisdorf, DJ	1
Gladstone, DE	1
Choi, I; Goto, T; Kozuru, M; Tobinai, K; Tokoro, A; Uike, N; Yufu, Y	1
Burian, C; Koziol, JA; Piro, LD; Saven, A	1
Gora-Tybor, J; Krykowski, E; Robak, T; Urbańska-Ryś, H	1
Bergmann, L; Chow, KU; Hansmann, ML; Hoelzer, D; Hossfeld, DK; Jäger, E; Meyer, A; Mitrou, PS; Peters, HD; Rummel, MJ	1
Burch, PA; Dinapoli, RP; Etzell, PS; Leitch, JM; Marks, RS; Morton, RF; Nair, S; O'Fallon, JR; Rajkumar, SV; Scheithauer, B	1
Corbett, WE; Daeninck, PJ; Eisenhauer, E; Johnston, JB; Wainman, N; Zaentz, SD	1
Kasznicki, M; Robak, T	1
Ghanima, W; Heldal, D; Tjønnfjord, GE	1
Barlogie, B; Desikan, KR; Dhodapkar, MV	1

Reviews

4 review(s) available for cladribine and Local Neoplasm Recurrence

Article	Year
Response to the Therapy in Hairy Cell Leukemia: Systematic Review and Meta-Analysis. Clinical lymphoma, myeloma & leukemia, 2018, Volume: 18, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Humans; Leukemia, Hairy Cell; Neoplasm Recurrence, Local; Remission Induction; Rituximab; Treatment Outcome; Vemurafenib	2018
Risk of additional cancers in untreated and treated hairy cell leukemia patients. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Incidence; Leukemia, Hairy Cell; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pentostatin	2010
Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia, 2002, Volume: 16, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cladribine; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Nucleosides; Survival Rate; Treatment Failure; Vidarabine	2002
Waldenström's macroglobulinemia. Current treatment options in oncology, 2000, Volume: 1, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; beta 2-Microglobulin; Chlorambucil; Cladribine; Clinical Trials as Topic; Combined Modality Therapy; Humans; Interferon-alpha; Neoplasm Recurrence, Local; Plasmapheresis; Rituximab; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia	2000

Trials

11 trial(s) available for cladribine and Local Neoplasm Recurrence

Article	Year
Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. Multiple sclerosis and related disorders, 2022, Volume: 57 Topics: Adult; Cladribine; Female; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Patient Satisfaction; Personal Satisfaction; Prospective Studies; Quality of Life; Tablets	2022
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms. Leukemia & lymphoma, 2023, Volume: 64, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Neoplasm Recurrence, Local	2023
A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas. International journal of cancer, 2021, 12-15, Volume: 149, Issue:12 Topics: Adolescent; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Busulfan; Cladribine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Transplantation Conditioning; Transplantation, Autologous; Young Adult	2021
A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. Clinical lymphoma, myeloma & leukemia, 2017, Volume: 17, Issue:12 Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Diarrhea; Drug Resistance, Neoplasm; Edema; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome	2017
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:10 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Rituximab; Sirolimus	2014
Treatment outcome in older patients with childhood acute myeloid leukemia. Cancer, 2012, Dec-15, Volume: 118, Issue:24 Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Transplantation, Autologous; Young Adult	2012
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial. Bone marrow transplantation, 2007, Volume: 39, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cladribine; Combined Modality Therapy; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2007
Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma. Leukemia & lymphoma, 1999, Volume: 32, Issue:3-4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Dexamethasone; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction	1999
Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:1 Topics: Aged; Antineoplastic Agents; Cladribine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Recurrence; Survival Rate; Treatment Outcome	1999
Phase II North Central Cancer Treatment Group study of 2-cholorodeoxyadenosine in patients with recurrent glioma. American journal of clinical oncology, 1999, Volume: 22, Issue:2 Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Cladribine; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis	1999
Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Seminars in oncology, 2000, Volume: 27, Issue:2 Suppl 5 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Canada; Cause of Death; Cladribine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Injections, Intravenous; Interferon-alpha; Leukemia, Hairy Cell; Longitudinal Studies; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pentostatin; Remission Induction; Survival Rate; Treatment Outcome	2000

Other Studies

27 other study(ies) available for cladribine and Local Neoplasm Recurrence

Article	Year
Identification of Novel Genes and Associated Drugs in Advanced Clear Cell Renal Cell Carcinoma by Bioinformatic Methods. The Tohoku journal of experimental medicine, 2022, Aug-26, Volume: 258, Issue:2 Topics: Biomarkers, Tumor; Carcinoma, Renal Cell; Cladribine; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Neoplasm Recurrence, Local; Prognosis; Protein Serine-Threonine Kinases	2022
Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma. Oncotarget, 2022, Volume: 13 Topics: Adult; Antigens, CD20; Cladribine; Epigenesis, Genetic; Humans; Immunologic Factors; Immunotherapy; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Rituximab; Vorinostat	2022
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Multiple sclerosis (Houndmills, Basingstoke, England), 2023, Volume: 29, Issue:6 Topics: Cladribine; Follow-Up Studies; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Tablets	2023
Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH. Blood advances, 2023, 09-26, Volume: 7, Issue:18 Topics: Child; Cladribine; Cytarabine; Histiocytosis, Langerhans-Cell; Humans; Neoplasm Recurrence, Local; Proto-Oncogene Proteins B-raf; Vemurafenib	2023
Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers. Journal of neuroimmunology, 2023, 09-15, Volume: 382 Topics: Cladribine; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Retrospective Studies; Tablets	2023
Re-induction with modified CLAG regimen in relapsed or refractory acute myeloid leukemia in children bridging to allogeneic hematopoietic stem cell transplantation. World journal of pediatrics : WJP, 2020, Volume: 16, Issue:2 Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Remission Induction; Retreatment; Retrospective Studies	2020
Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy. Cancer medicine, 2021, Volume: 10, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate	2021
A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. Multiple sclerosis and related disorders, 2021, Volume: 52 Topics: Alemtuzumab; Cladribine; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Retrospective Studies	2021
Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment. Multiple sclerosis (Houndmills, Basingstoke, England), 2021, Volume: 27, Issue:12 Topics: Cladribine; Glomerulonephritis; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local	2021
Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report. BMC cancer, 2019, Mar-18, Volume: 19, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Siblings; Transplantation, Haploidentical; Treatment Outcome	2019
Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunotherapy; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Rituximab; Splenic Neoplasms; Treatment Outcome	2013
[IgA vasculitis revealing hairy cell leukemia relapse treated by cladribine]. Presse medicale (Paris, France : 1983), 2014, Volume: 43, Issue:3 Topics: Aged; Antineoplastic Agents; Cladribine; Diagnosis, Differential; Glomerulonephritis, IGA; Humans; Leukemia, Hairy Cell; Male; Neoplasm Recurrence, Local; Vasculitis, Leukocytoclastic, Cutaneous	2014
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood, 2017, 02-02, Volume: 129, Issue:5 Topics: Antineoplastic Agents; Cladribine; Disease Management; Humans; Leukemia, Hairy Cell; Neoplasm Recurrence, Local; Neoplasm, Residual; Pentostatin; Treatment Outcome	2017
Interferon-alpha is a very effective salvage therapy for patients with hairy cell leukemia relapsing after cladribine: a report of three cases. Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:4 Topics: Aged; Antineoplastic Agents; Cladribine; Humans; Interferon-alpha; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy	2011
Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. Leukemia & lymphoma, 2010, Volume: 51, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cladribine; Equilibrative Nucleoside Transporter 1; Female; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Infusions, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Transport Proteins; Middle Aged; Neoplasm Recurrence, Local; Reverse Transcriptase Polymerase Chain Reaction; Rituximab; RNA, Messenger; Salvage Therapy; Survival Rate; Treatment Outcome	2010
Salvaging AML with CLAG: novel option, or more of the same? Leukemia research, 2011, Volume: 35, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome	2011
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leukemia research, 2011, Volume: 35, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult	2011
Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Seminars in oncology, 2002, Volume: 29, Issue:4 Suppl 13 Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Cladribine; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy; Vidarabine	2002
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-01, Volume: 21, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Interferons; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pentostatin; Remission Induction; Splenectomy; Survival Rate; Treatment Outcome	2003
An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia, 2004, Volume: 18, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Cohort Studies; Female; Follow-Up Studies; Humans; Interferon-alpha; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Second Primary; Palliative Care; Pentostatin; Splenectomy; Survival Rate; Treatment Outcome	2004
[Cladribine monotherapy for patients with relapsed or refractory indolent non-Hodgkin lymphoma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2004, Volume: 45, Issue:7 Topics: Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome	2004
Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma. Oncology, 2004, Volume: 66, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 18; Cladribine; Female; Helicobacter Infections; Helicobacter pylori; Humans; In Situ Hybridization, Fluorescence; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Translocation, Genetic; Treatment Outcome	2004
Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine. Leukemia & lymphoma, 2006, Volume: 47, Issue:9 Topics: Adolescent; Child; Child, Preschool; Cladribine; Disease-Free Survival; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Infant; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Treatment Outcome	2006
Refractory Waldenström's macroglobulinaemia responsive to 2-chlorodeoxyadenosine and mycophenolate mofetil. Leukemia research, 2008, Volume: 32, Issue:9 Topics: Cladribine; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Middle Aged; Mycophenolic Acid; Neoplasm Recurrence, Local; Treatment Outcome; Waldenstrom Macroglobulinemia	2008
Adult T-cell leukemia-lymphoma successfully treated with 2-chlorodeoxyadenosine. Internal medicine (Tokyo, Japan), 1998, Volume: 37, Issue:4 Topics: Aged; Antineoplastic Agents; Cladribine; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia-Lymphoma, Adult T-Cell; Male; Neoplasm Recurrence, Local	1998
Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood, 1998, Sep-15, Volume: 92, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Interferons; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pentostatin; Remission Induction; Splenectomy; Survival Analysis; Treatment Failure	1998
[Hairy cell leukemia treated with cladribine]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2002, Apr-30, Volume: 122, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prospective Studies; Remission Induction; Treatment Outcome	2002